
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd demonstrates a strong positive outlook due to its innovative products, including the Collink.3D bioink, which has shown superior performance in structured tissue formation compared to traditional animal-derived options, thus positioning the company competitively against established suppliers. The operational U.S.-based logistics center is anticipated to drive incremental sales growth for its BioInk and rhCollagen products, particularly within research institutions and tissue-engineering customers, further enhancing revenue potential. Additionally, the company's strategic partnership with Allergan for the development of dermal fillers and the encouraging data supporting the effectiveness of its rhCollagen for tissue modeling and drug testing underscore the potential for significant market expansion and improved cash flow.
Bears say
CollPlant Biotechnologies Ltd faces significant headwinds reflected in its recent capital raise, which has prompted a disproportionate negative reaction in its stock price. The company’s choice to price its recent financing at $1.25 per share indicates ongoing pressure on its equity and suggests constrained capacity for future capital formation, likely affecting investor confidence. Additionally, lowered forecasts for key products such as Dermal Fillers and BioInk, along with the removal of Breast Implants from operational models, highlight the challenges the company faces in developing its offerings within the regenerative and aesthetic medicine sectors.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares